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To the Editor,
Mucositis is a common sequel of radio- (DXR) 
and/or chemo-(CXR)-therapy in patients with cancer, 
with direct and significant impact on the quality of 
life and cost of care. Mucositis also affects survival, 
because of the risk of infection. (1) Ulcerations in 
the oro-esophageal and gastrointestinal mucosae 
resulting in pain, dysphagia, diarrhea and 
dysfunction, depending on the tissue affected, 
are typical symptoms of mucositis. In  patients 
undergoing high-dose conditioning regimen for 
hematopoietic stem cell transplant (HSCT), the 
risk of oral and gastrointestinal mucositis is up to 
100%. After HSCT, in addition to OM, therapy-
induced myelosuppression causes significant risk 
of bacteremia and sepsis from oral microorganisms 
resulting in increased days of fever, antibiotic 
use and hospitalization (1). From the patient’s 
Oral mucositis (OM) may occur in up to 100% of patients undergoing condition regimen to hematopoietic 
stem cell transplant (HSCT). From the patient’s perspective, OM is one of the most debilitating side effects 
of transplantation. It is commonly thought that oral hygiene can modify the incidence and severity of oral 
mucositis, therefore professional oral health care (POHC) is recommended prior to conditioning regimen 
for HSCT. A new strategy for the treatment of OM is sodium hyaluronate (SH) combined with amino 
acid precursors of collagen (Aas) (Mucosamin®). SH is a mucoaderent polymer acting as a mechanical 
barrier and pain reliever. Furthermore, it allows prolonged contact of the product with the mucous 
membrane. In this study, a total of 68 adult patients due to undergo HSCT for allogenic and autologous 
transplant were enrolled at the Stem Cell Transplant Unit. The patients were divided into two groups. 
One group was treated with POHC before HSCT and applications of Mucosamin® during the recovery 
after transplantation. The second group served as controls, with the usual treatment of Clorexidine 0.20% 
adopted by the department. After HSCT the same clinician, an expert in oral medicine trained for the 
clinical trial, evaluated symptoms of the patients’ mucositis of both groups every day. The treated patients 
developed less severe OM, therefore Mucosamin® seems to have a protective role against the more severe 
phases of mucositis. The maximum OM pain, measured with the VAS scale, was higher in patients who did 
not use Mucosamin®. In the treated group OM resolved sooner than in the control group.
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MATERIALS AND METHODS
Patient characteristics 
We designed a case control study. A total of 68 adult 
patients (average age 51, range 22-70) prepared for HSCT 
for allogenic and autologous transplant were recruited at 
the Stem Cell Transplant Unit, Città della Salute e della 
Scienza of Turin, and in the Oral Surgery Department, 
Dental School, University of Turin. 
Criteria for inclusion were: i) age> 18 years; ii) due for 
HSCT; iii) informed consent and ability to complete the 
trial. Exclusion criteria included: i) known allergy to any 
of the components of the compound; ii) inability to check 
results; iii) patients with systemic disease, other than 
hematological malignancies, which impair wound healing 
(i.e. diabetes); iv) muco-cutaneous diseases; v) not been 
able/willing to give informed consent.
This study was approved by the Institutional Review 
Board of our Center and conducted according to the 
Declaration of Helsinki and all patients provided written 
informed consent to participate in the study.
Treatment plan
We asked each patient to complete: i) a survey regarding 
oral hygiene to assess the individual knowledge of the 
correct oral hygiene procedures and patient compliance; 
ii) a survey regarding radio/chemotherapy and OM to 
investigate the level of knowledge of the patient on 
interactions between drugs, radio and chemotherapy on 
the oral cavity, and of mucositis.
Group A included patients sent by the Haematology 
Departments to the Dental School to eliminate infectious 
foci of the oral cavity, which is mandatory in order to 
receive the suitability for transplantation. The patients 
underwent careful intra and extra oral examination, and 
radiological investigations to assess the need for dental 
treatment, compatible with the timing of transplantation. 
All patients in Group A had a periodontal chart analysing: 
i) O’Leary Index Plaque (Plaque Control Record); ii) 
Bleeding index; ii) Periodontal Screening and Recording 
Index (PSR) (11). Each of them received a complete 
session of professional oral hygiene, with scaling and root 
planing. At the end of each session, patients were educated 
on the correlation between oral health and OM and possible 
complications, and were instructed on correct home oral 
hygiene procedures and were motivated to maintain such 
perspective, OM is one of transplantation’s most 
debilitating side effects (2).
The pathogenesis of OM associated to 
chemotherapy or radiation results from nonspecific 
direct effects of radiation or chemotherapy on 
rapidly dividing mucosal basal cells; the initial 
phase involves direct damage to DNA and other 
cellular components that occurs immediately after 
exposure to radiation or chemotherapy (3). The 
ulcerated surface can be colonized by oral bacteria, 
resulting in production of toxins, additional 
inflammatory cytokines and angiogenic factors, 
which may cause bacteremia and sepsis in the 
presence of granulocytopenia (4). 
Most reports concerning dental management 
during HSCT recommend mouth rinses or use of 
antibiotic pastilles for oral decontamination (5), 
however, these have been found ineffective in 
preventing OM (6). The microorganism in the mouth 
contains hundreds of species of bacteria as complex, 
mixed, interdependent colonies in biofilms, and 
adheres to the teeth (7). The biofilm protects the 
adhering bacteria against environmental attacks. 
Antibiotics or oral rinses, without the mechanical 
removal of plaque (i.e. tooth brushing), are unable 
to penetrate the plaque to reach the linking film 
bacteria (8, 9). Almost all patients understand that 
regular brushing is very important for oral hygiene, 
but few of them brush properly. This is why 
professional and repeated instruction on brushing is 
critical for controlling plaque.
A new strategy for the treatment of OM is the 
sodium hyaluronate (SH) combined with amino acid 
precursors of collagen (Aas) (Mucosamin®). SH 
is a mucoaderent polymer acting as a mechanical 
barrier and pain reliever. As induce, the production 
of collagen and glycosaminoglycan by fibroblasts, 
a key element for the recovery of the tissue during 
the healing process, as demonstrate in a study by 
Colella (10).
The aim of the study was to evaluate the clinical 
efficacy of Mucosamin® in wound healing and pain 
management in OM after HSCT.  We also evaluated 
the importance of professional oral hygiene by a 
dental hygienist to reduce the severity of OM in 
combination with the Mucosamin®.
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Statistical analysis
The results included continuous and categorical 
variables. The former are reported as mean and standard 
deviation. Nonparametric tests were used: the Wilcoxon 
signed-rank test for comparisons of two correlated 
samples involving matched pairs and the Mann-Whitney 
test for comparisons of two independent distributions. 
Categorical variables, reported as count and percentage, 
were arranged in cross-correlation tables and compared 
using the χ2 test with the Yates correction when all 
expected values were higher than 5 or Fisher’s exact test. 
Statistical significance corresponded to a probability less 
than 0.05 that differences could be ascribed to chance.
RESULTS
Patient characteristics
Table I shows the demographic details of the 
patients and other baseline information. The sample 
is homogeneous for age and sex. All patients were 
candidates for HSTC for hematological malignancies. 
Thirty-two patients were in group A and 28 in group 
B. Eight patients previously enrolled in the study did 
not proceed with the transplant because of their poor 
general health condition, death or lack of available 
donor. In both groups, the predominant pathology 
was acute myeloid leukemia. Two patients in group 
A and 4 patients in group B were treated with Total 
Body Irradiation (TBI) and chemotherapy while the 
other patients underwent a conditioning regimen 
of only high-dose chemotherapy. Three patients 
in group A and 6 in group B did not develop OM. 
Patients who did not developed mucositis, were 
excluded from the results.
Treatment administration
There was no indication of any intolerance to 
the product. Based on the interview we conducted 
during the study, all patients except one, liked the 
consistency of the product in the mouth and they were 
able to use it during the day based on the instructions 
of the dentist. There were no differences in OM 
location among patients receiving Mucosamin® 
(group A) and in those who did not (group B).
Patients in group A who used Mucosamin® on 
initial lesions developed less severe OM, while 
procedures during the period of hospitalization. Patients 
who presented periodontal problems underwent a second 
hygiene session for scaling and root planing of pathological 
sites. Patients who required further dental treatment, such 
as conservative treatment, endodontic or extraction, were 
re-motivated to maintaining a high standard of oral hygiene 
during the session in which they were given the suitability 
for transplantation. Furthermore, patients in group A were 
instructed by a single doctor to recognize symptoms of 
OM and to apply SH-AAs based spray on these lesions 
3-4 times a day after a meal and oral hygiene, keeping the 
liquid in situ for at least 2 minutes and to avoid drinking, 
eating and rinsing the mouth for at least one hour. The 
same doctor controlled the patients during hospitalization 
in order to recognize initial and advanced signs of OM and 
to remind patients how to apply the compound.  
Patients in Group B were recruited directly in the 
Haematology department, depending on availability of 
patients, but they were not visited in Dentistry department. 
They were not involved in dental hygiene sessions and 
did not receive Mucosamin® but they received the usual 
treatment of Clorexidine 0.20%.  Also, we asked the 
patients whether they had undergone a session of dental 
hygiene during the 6 months prior to the transplantation. 
Starting the day after HSCT, the same expert trained 
for the clinical trial, evaluated patients of both group every 
day, during hospitalization. The evaluation included three 
scores for OM: i) WHO mucositis scale ranging from 0= 
no symptoms; 1=soreness, erythema; 2=erythema, ulcers 
but able to eat solids (12); 3=ulcers but required liquid diet; 
4=oral alimentation not possible; ii) Visual analogue scale 
(VAS) ranging from 0=no pain to 10=worst pain in the 
world (13); iii) OMAS scale (Oral Mucositis Assessment 
Scale): Oral cavity for Ulceration 0=No lesion; 1= Lesion 
<1 cm2; 2=Lesion 1 to 3 cm2; 3=Lesion >3 cm2; Oral cavity 
for Erythema: 0= None; 1=Not severe; 2=Severe (14).
According to WHO and OMAS scales, we divided the 
lesions into two groups: light mucositis (WHO grade 1 and 
2, OMAS grade 1) and severe mucositis (WHO grade 3 and 
4, OMAS grade 2 and 3). Primary indicators of mucositis 
were the degrees of ulceration and redness measured in 
specific sites in the mouth. Secondary indicators included 
oral pain, difficulty swallowing and the ability to eat as 
assessed by the patient. A single score is not produced 
from this scale, rather a score for ulceration and redness 
based on different locations in the mouth are used.
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Table I.  Patients’ baseline characteristics.
  Group A Group B
 no. 32 28
Sex M 14 (49%) 14 (50%)
F 18 (51%) 14 (50%)
Age
< 30 y. 3 (9%) 2 (6%)
31 - 40 y. 5 (16%) 1 (16%)
41-50 y. 9 (28%) 6 (23%)
51 - 60 y. 10 (31%) 9 (32%)
> 60 y. 5 (16%) 10 (33%)
Transplant
Autologous 5 (16%) 6 (26%)
Allogenic 27 (84 %) 22 (74%)
Conditioning 
Regimen
TBI 2 (6 %) 4 (14%)
Non TBI 30 (94 %) 24 (86%)
Pathology
Acute Myeloid Leukaemia 8 (25 %) 9 (34%)
Chronic Myeloid leukaemia 4 (13%) 1 (3%)
Hodgkin’s Lymphoma 3 (9%) 1 (3%)
Non Hodgkin’s Lymphoma 8 (25%) 7 (26%)
Myelofibrosis 1 (3%) 0 (0%)
Multiple Myeloma 2 (6%) 6 (23%)
Myelodysplastic Syndrome 6 (19%) 4 (10%)
M: Male; F: Female; TBI: Total Body Irradiation
Table II. Evaluation of gravity of oral mucositis related to use of Mucosamin and a session of POHC.
Light 
Mucositis
Severe 
Mucositis
Group A 20 9
P=0.02 * 
RR=0.49 *
Group B 8 14
Group A1 19 7
P=0.006 *
RR=0.38 *
Group CTRL 5 12
Group A= Mucosamin group; Group B=No Mucosamin group. Group A1 (Mucosamin and oral hygiene within 6 months from 
HSTC) Group CTRL (No Mucosamin and oral hygiene more than 6 months from HSTC). P<0.05 *statistically significant.
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in agreement with several studies that emphasize the 
importance of effective control of plaque, because 
oral health conditions are among the most important 
risk factors for the development of mucositis (15). 
Our results also corroborate the importance of the 
role of the dental hygienist and confirm the necessity 
of creating a team hematologist-dentist-hygienist 
for management of complications of the oral cavity 
in patients undergoing bone marrow transplant. 
Furthermore, when Mucosamin® and POHC are 
associated, the risk of developing higher grades  of 
mucositis is strongly reduced.
According to our study, the use of Mucosamin® 
can influence the type and severity of oral mucositis, 
allowing patients to have a better quality of life. 
The efficacy of Mucosamin® in decreasing pain 
and accelerating wound healing relies on its ability 
in tissue repair, activation and modulation of 
inflammatory responses, promoting the proliferation 
and cell migration, angiogenesis, increased re-
epithelialization, born of basal keratinocytes and 
collagen deposition, thus acting on ulcerative 
mucositis by forming a protective layer.
The analysis of our data showed that the 
combination of a recent POHC, appropriate 
oral hygiene during hospitalization and use of 
Mucosamin® exponentially reduces the severity/
duration of mucositis, as well as the discomfort of the 
patient. Finally, we can say that using Mucosamin® 
also determines a reduction in the extent of the 
lesions induced by chemotherapies. This spray based 
on hyaluronic acid and amino acids can be a valid 
therapeutic aid in the treatment of mucositis.
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